Novavax Valuation
| NVV1 Stock | EUR 8.38 0.53 5.95% |
At this time, the firm appears to be fairly valued. Novavax secures a last-minute Real Value of €8.2 per share. The latest price of the firm is €8.38. Our model forecasts the value of Novavax from analyzing the firm fundamentals such as Profit Margin of (0.72) %, return on equity of -8.98, and Current Valuation of 484 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Novavax's price fluctuation is moderately volatile at this time. Calculation of the real value of Novavax is based on 3 months time horizon. Increasing Novavax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novavax stock is determined by what a typical buyer is willing to pay for full or partial control of Novavax. Since Novavax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novavax Stock. However, Novavax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.38 | Real 8.2 | Hype 8.38 | Naive 8.74 |
The real value of Novavax Stock, also known as its intrinsic value, is the underlying worth of Novavax Company, which is reflected in its stock price. It is based on Novavax's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novavax's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novavax helps investors to forecast how Novavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novavax more accurately as focusing exclusively on Novavax's fundamentals will not take into account other important factors: Novavax Total Value Analysis
Novavax is now anticipated to have takeover price of 484 M with market capitalization of 727.55 M, debt of 323.46 M, and cash on hands of 1.57 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novavax fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
484 M | 727.55 M | 323.46 M | 1.57 B |
Novavax Investor Information
About 62.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 15.18. Novavax had not issued any dividends in recent years. The entity had 1:20 split on the 10th of May 2019. Based on the key measurements obtained from Novavax's financial statements, Novavax is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Novavax Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novavax has an asset utilization ratio of 44.49 percent. This implies that the Company is making €0.44 for each dollar of assets. An increasing asset utilization means that Novavax is more efficient with each dollar of assets it utilizes for everyday operations.Novavax Ownership Allocation
Novavax maintains a total of 85 Million outstanding shares. Over half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novavax Profitability Analysis
The company reported the revenue of 1.15 B. Net Loss for the year was (1.74 B) with loss before overhead, payroll, taxes, and interest of (1.39 B).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novavax's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novavax and how it compares across the competition.
About Novavax Valuation
The stock valuation mechanism determines Novavax's current worth on a weekly basis. Our valuation model uses a comparative analysis of Novavax. We calculate exposure to Novavax's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novavax's related companies.Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people.
8 Steps to conduct Novavax's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novavax's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novavax's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novavax's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novavax's revenue streams: Identify Novavax's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novavax's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novavax's growth potential: Evaluate Novavax's management, business model, and growth potential.
- Determine Novavax's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novavax's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |